Non-vitamin K antagonist oral anticoagulants such as edoxaban are the standard of care for
stroke prevention in patients with atrial fibrillation (AF). The Global Edoxaban Treatment in …

Atrial fibrillation is a very common arrhythmia whose prevalence is expected to increase
significantly as the population ages. The associated stroke risk is a major cause of morbidity …

During the last decade, non-vitamin K antagonist oral anticoagulants (NOACs)
revolutionized the thromboprophylaxis management of several medical conditions, including …

Introduction Guidelines for imaging anticoagulated patients following a traumatic injury are
unclear. Interval CT head (CTH) is often routinely performed after initial negative CTH to …

Backgrounds Non-vitamin K antagonist oral anticoagulants (NOACs) have been
recommended as the first choice over warfarin for non-valvular atrial fibrillation (AF) …

Atrial fibrillation is the most common cardiac arrhythmia and an independent risk factor for
stroke. Oral anticoagulant therapy has a crucial role in the prevention of stroke and other …

Background We compared the outcomes and adverse events of TAVI patients based on the
discharge and long‐term antiplatelet or anticoagulant treatment regimens (single antiplatelet …

Background: Major atrial fibrillation (AF) guidelines recommend non-vitamin K antagonist
oral anticoagulants (NOACs) over warfarin, except in rare clinical circumstances based on 4 …

Atrial fibrillation is the most common clinically significant arrhythmia that may be
encountered by general and specialist doctors. This disorder increases the risk of a …

Most atrial fibrillation (AF) patients need anticoagulation management to reduce the risk of
thromboembolic events and stroke. Currently, two major drug therapies are available …